中国肺癌杂志Issue(12)：850-854,5.DOI:10.3779/j.issn.1009-3419.2014.12.05
ALK阳性非小细胞肺癌靶向治疗研究进展
Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
摘要
Abstract
hTe rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. hTe ifrst-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors repre-sent a signiifcant advance in the evolution of personalized medicine for NSCLC. A randomized phase III clinical trial in which superiority of crizotinib over chemotherapy was seen in previously treated ALK-positive NSCLC patients demonstrated dura-ble responses and well tolerance in the majority of ALK-positive NSCLC patients treated with crizotinib. However, despite the initial responses, most patients develop acquired resistance to crizotinib. Several novel therapeutic approaches targeting ALK-positive NSCLC are currently under evaluation in clinical trials, including second-generation ALK inhibitors, such as LDK378, CH5424802 (RO5424802), and AP26113, and new agents shock protein 90 inhibitors. hTis review aims to present the current knowledge on this fusion gene, the treatment advances, and novel drug clinical trials in ALK rearranged NSCLC.关键词
ALK/肺肿瘤/克唑替尼Key words
ALK/Lung neoplasms/Crizotinib引用本文复制引用
马丽,张树才..ALK阳性非小细胞肺癌靶向治疗研究进展[J].中国肺癌杂志,2014,(12):850-854,5.基金项目
hTis study was supported by the grant from the Beijing Excellent Talent Training Fund (to Shucai ZHANG)(No.2013 D003034000015).本研究受北京市优秀人才培养项目（No.2013D003034000015）资助 （to Shucai ZHANG）
